抗帕金森病药雷沙吉兰的药理作用和临床评价

Pharmacological effects and clinical evaluation of rasagiline:a new drug for Parkinson disease

帕金森病是一种常见的中老年神经系统退行性疾病,随着人口老龄化,其发病率逐年上升,给家庭和社会造成了沉重负担。雷沙吉兰(rasagiline)是一种新型有效的帕金森病治疗药物,由Lundbeck公司和Teva公司联合开发,该药于2005年1月获准在以色列上市,2005年2月获欧盟批准,2006年5月获FDA批准在美国上市,2017年6月批准在中国上市。雷沙吉兰为不可逆性B型单胺氧化酶选择性抑制剂,能够抑制多巴胺降解,增加多巴胺蓄积,促进多巴胺的释放,改善PD患者的临床症状。本文就其药理作用、临床评价、安全性等进行综述。

Parkinson＇s disease is a common neurodegenerative disease in the elderly. As the population ages, its incidence increases year by year, causing a heavy burden on families and society. Rasagiline is a new and effective therapeutic agent for Parkinson＇s disease. It was jointly developed by Lundbeck and Teva. The drug was approved for listing in Israel in January 2005, followed by February 2005 in the European Union, May 2006 in the United States and July 2017 in China. Rasagiline is an irreversible B-type monoamine oxidase selective inhibitor that shows the roles of inhibiting dopamine degradation, increasing dopamine accumulation, promoting dopamine release, and improving clinical symptoms in patients with PD. This article reviews the pharmacological effects, clinical evaluation and safety.